Intra-Cellular Therapies Inc
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The … Read more
Intra-Cellular Therapies Inc (ITCI) - Net Assets
Latest net assets as of December 2024: $1.15 Billion USD
Based on the latest financial reports, Intra-Cellular Therapies Inc (ITCI) has net assets worth $1.15 Billion USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.37 Billion) and total liabilities ($218.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.15 Billion |
| % of Total Assets | 84.02% |
| Annual Growth Rate | 37.73% |
| 5-Year Change | 74.84% |
| 10-Year Change | 141.15% |
| Growth Volatility | 117.66 |
Intra-Cellular Therapies Inc - Net Assets Trend (2011–2024)
This chart illustrates how Intra-Cellular Therapies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intra-Cellular Therapies Inc (2011–2024)
The table below shows the annual net assets of Intra-Cellular Therapies Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.15 Billion | +94.19% |
| 2023-12-31 | $591.42 Million | -9.85% |
| 2022-12-31 | $656.07 Million | +57.00% |
| 2021-12-31 | $417.89 Million | -36.38% |
| 2020-12-31 | $656.86 Million | +236.84% |
| 2019-12-31 | $195.01 Million | -38.62% |
| 2018-12-31 | $317.71 Million | -30.09% |
| 2017-12-31 | $454.44 Million | +21.02% |
| 2016-12-31 | $375.50 Million | -21.15% |
| 2015-12-31 | $476.24 Million | +295.04% |
| 2014-12-31 | $120.55 Million | +281.32% |
| 2013-12-31 | $31.62 Million | +86.15% |
| 2012-12-31 | $16.98 Million | -5.07% |
| 2011-12-31 | $17.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intra-Cellular Therapies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 169183600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Comprehensive Income | $191.00K | 0.02% |
| Other Components | $2.84 Billion | 247.30% |
| Total Equity | $1.15 Billion | 100.00% |
Intra-Cellular Therapies Inc Competitors by Market Cap
The table below lists competitors of Intra-Cellular Therapies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fortescue Metals Group Ltd
OTCQX:FSUMF
|
$13.82 Billion |
|
Dawning Information Industry Co Ltd
SHG:603019
|
$13.83 Billion |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
$13.83 Billion |
|
Repsol S.A
OTCQX:REPYF
|
$13.85 Billion |
|
Repsol SA
OTCQX:REPYY
|
$13.82 Billion |
|
Coca-Cola Consolidated Inc.
NASDAQ:COKE
|
$13.80 Billion |
|
ANTA Sports Products Ltd
PINK:ANPDF
|
$13.79 Billion |
|
Kasikornbank Public Co Ltd
PINK:KPCPY
|
$13.78 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intra-Cellular Therapies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 591,424,000 to 1,148,460,000, a change of 557,036,000 (94.2%).
- Net loss of 74,676,000 reduced equity.
- New share issuances of 543,086,000 increased equity.
- Other comprehensive income increased equity by 87,000.
- Other factors increased equity by 88,539,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.68 Million | -6.5% |
| Share Issuances | $543.09 Million | +47.29% |
| Other Comprehensive Income | $87.00K | +0.01% |
| Other Changes | $88.54 Million | +7.71% |
| Total Change | $- | 94.19% |
Book Value vs Market Value Analysis
This analysis compares Intra-Cellular Therapies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 44.22x to 11.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $2.98 | $131.87 | x |
| 2012-12-31 | $0.77 | $131.87 | x |
| 2013-12-31 | $1.83 | $131.87 | x |
| 2014-12-31 | $4.21 | $131.87 | x |
| 2015-12-31 | $13.20 | $131.87 | x |
| 2016-12-31 | $8.68 | $131.87 | x |
| 2017-12-31 | $9.84 | $131.87 | x |
| 2018-12-31 | $5.81 | $131.87 | x |
| 2019-12-31 | $3.53 | $131.87 | x |
| 2020-12-31 | $9.34 | $131.87 | x |
| 2021-12-31 | $5.14 | $131.87 | x |
| 2022-12-31 | $6.98 | $131.87 | x |
| 2023-12-31 | $6.17 | $131.87 | x |
| 2024-12-31 | $11.14 | $131.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intra-Cellular Therapies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.97%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.19x
- Recent ROE (-6.50%) is above the historical average (-36.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 61.99% | 47.48% | 0.99x | 1.32x | $9.30 Million |
| 2012 | -97.68% | -532.10% | 0.16x | 1.17x | $-18.29 Million |
| 2013 | -84.98% | -981.67% | 0.07x | 1.22x | $-30.03 Million |
| 2014 | -25.46% | -5316.37% | 0.00x | 1.09x | $-42.75 Million |
| 2015 | -22.00% | -114698.50% | 0.00x | 1.02x | $-152.42 Million |
| 2016 | -31.01% | -35205.79% | 0.00x | 1.04x | $-153.98 Million |
| 2017 | -21.52% | -39771.64% | 0.00x | 1.04x | $-143.22 Million |
| 2018 | -48.83% | 0.00% | 0.00x | 1.12x | $-186.90 Million |
| 2019 | -75.75% | -243713.69% | 0.00x | 1.29x | $-167.22 Million |
| 2020 | -34.56% | -1007.54% | 0.03x | 1.09x | $-292.69 Million |
| 2021 | -67.99% | -347.73% | 0.17x | 1.17x | $-325.91 Million |
| 2022 | -39.06% | -102.86% | 0.33x | 1.15x | $-321.86 Million |
| 2023 | -23.62% | -30.08% | 0.64x | 1.23x | $-198.82 Million |
| 2024 | -6.50% | -10.97% | 0.50x | 1.19x | $-189.52 Million |
Industry Comparison
This section compares Intra-Cellular Therapies Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $580,491,146
- Average return on equity (ROE) among peers: -45.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intra-Cellular Therapies Inc (ITCI) | $1.15 Billion | 61.99% | 0.19x | $13.82 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $14.78 Million | -64.19% | 0.99x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-241.47K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -329.21% | 0.78x | $194.64 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $37.06 Million | 39.05% | 0.16x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $32.70 Million | -18.88% | 0.16x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.84 |
| Adcock Ingram Holdings Limited (AIHLF) | $4.54 Billion | 14.90% | 0.58x | $85.61 Million |